Skip Navigation
 
 
 
 xxx
 
 
 
 
 
 
 
 
 
Print This Page
Share this page: More
 

Kathy N. Williams

Kathy Williams
Email:

kathyw@jhu.edu

My primary research interest is the experimental chemotherapy of Mycobacterium tuberculosis. I work with Drs. Nuermberger and Grosset on various murine models, testing both active and latent tuberculosis to determine the efficacy of promising drugs to treat both active and latent tuberculosis. Our ultimate goal is to identify drugs, which can be used to in conjunction with the standard regimens or as replacements for current therapies to shorten the standard treatment time, or at the very least improve the efficacy of the current therapies.
 
I am also involved in a project using an in vitro pharmacodynamic system to better understand drug efficacy and the selection of drug resistant mutants, and in another project testing the efficacy of drugs used to treat
Streptococcus pneumoniae.

Publications

To read some of these publications online, click here. Please note that to read the full text of some of these articles requires that you have an online subscription to the journal.

1.    Williams, K.N., C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-9.

2.    Tasneen, R., S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 52:3664-8.

3.    Nuermberger, E., S. Tyagi, R. Tasneen, K.N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-4.

4.    Rosenthal, I. M., M. Zhang, K.N. Williams, C. A. Peloquin, S. Tyagi, A. A. Vernon, W. R. Bishai, R. E. Chaisson, J. H. Grosset, and E. L. Nuermberger. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344.

5.    Rosenthal, I. M., K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 174:94-101.

6.    Nuermberger, E., I. Rosenthal, S. Tyagi, K.N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-5.

7.    Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-93.

8.    Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med 172:1457-62.

9.    Nuermberger, E., S. Tyagi, K.N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset. 2005. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 172:1452-6.

10.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-4.

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer